{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:12:06Z","timestamp":1790788326194,"version":"4.1.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,15]]},"DOI":"10.2169\/internalmedicine.4996-24","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:12:41Z","timestamp":1739812361000},"page":"2433-2438","source":"Crossref","is-referenced-by-count":4,"title":["Multimodal Treatment Approach for Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Gallbladder: A Patient with a Favorable Survival Outcome"],"prefix":"10.2169","volume":"64","author":[{"given":"Shinji","family":"Oe","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"},{"name":"Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Uchihara","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"},{"name":"Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Surgery 1, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Surgery 1, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Harada","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schimmack S, Svejda B, Lawrence B, et al. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 396: 273-298, 2011.","DOI":"10.1007\/s00423-011-0739-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cho MY, Kim JM, Sohn JH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 44: 157-165, 2012.","DOI":"10.4143\/crt.2012.44.3.157"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Roa I, de Aretxabala X, Araya JC, et al. Preneoplastic lesions in gallbladder cancer. J Surg Oncol 93: 615-623, 2006.","DOI":"10.1002\/jso.20527"},{"key":"4","unstructured":"4. Lloyd RV, Osamura RY, Kl\u00f6ppel G, et al. WHO Classification of tumours of Endocrine Organs. 4th ed. International Agency for Research on Cancer, Lyon, 2017: 355."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Frizziero M, Chakrabarty B, Nagy B, et al. Mixed neuroendocrine non-neuroendocrine neoplasms: a systematic review of a controversial and underestimated diagnosis. J Clin Med 9: 273, 2020.","DOI":"10.3390\/jcm9010273"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yao JC, Hassan M, Phan A, et al. One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072, 2008.","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"7","unstructured":"7. Adsay NV, La RS. Tumours of the gallbladder and extrahepatic bile duct. In: Digestive System Tumours\/WHO Classification of Tumours Editorial Board, 5th ed. WHO, Lyon, 2019: 292-294."},{"key":"8","unstructured":"8. Morizane C, Machida N, Honma Y, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol 8: 1447-1455, 2022."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nandy K, Patkar S, Yadav S, et al. Neuroendocrine neoplasms of the gallbladder: a single institute analysis of outcomes and prognostic factors. J Surg Oncol 129: 1121-1130, 2024.","DOI":"10.1002\/jso.27600"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Song H, Yang S, Zhang Y, et al. Comprehensive analysis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs): a SEER database analysis of 767 cases. Front Oncol 12: 1007317, 2023.","DOI":"10.3389\/fonc.2022.1007317"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zhang P, Li Z, Li J, et al. Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm. Cancer Med 10: 4855-4863, 2021.","DOI":"10.1002\/cam4.4031"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. McNamara MG, Swain J, Craig Z, et al. NET-02: a randomised, non-comparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. EClinicalMedicine 60: 102015, 2023.","DOI":"10.1016\/j.eclinm.2023.102015"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McGarrah PW, Leventakos K, Hobday TJ, et al. Efficacy of second-line chemotherapy in extrapulmonary neuroendocrine carcinoma. Pancreas 49: 529-533, 2020.","DOI":"10.1097\/MPA.0000000000001529"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1: EVIDoa2200015, 2022.","DOI":"10.1056\/EVIDoa2200015"},{"key":"15","unstructured":"15. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401: 1853-1865, 2023."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Liu C, Hua X, Yang Z, et al. Response with immunotherapy in a patient with mixed neuroendocrine non-neuroendocrine neoplasms of the gallbladder. Front Oncol 11: 770156, 2021.","DOI":"10.3389\/fonc.2021.770156"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Singh S, Halperin D, Myrehaug S, et al. [<sup>177<\/sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403: 2807-2817, 2024.","DOI":"10.1016\/S0140-6736(24)00701-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zhang J, Kulkarni HR, Singh A, Niepsch K, M\u00fcller D, Baum RP. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med 60: 377-385, 2019.","DOI":"10.2967\/jnumed.118.215848"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4996-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T03:43:43Z","timestamp":1755315823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4996-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":18,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4996-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"4996-24"}}